General Information of the Disease (ID: M6ADIS0228)
Name
Leukemogenesis
ICD
ICD-11: 2A82
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 6 item(s) under this disease
Crosstalk ID: M6ACROT05719
m6A Regulator YTH domain-containing protein 1 (YTHDC1)
m6A Target Circ_TET2
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Drug CP028
Crosstalk ID: M6ACROT05720
m6A Regulator YTH domain-containing protein 1 (YTHDC1)
m6A Target Circ_TET2
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Drug dactolisib
Crosstalk ID: M6ACROT05721
m6A Regulator YTH domain-containing protein 1 (YTHDC1)
m6A Target Circ_TET2
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Drug perhexiline
Crosstalk ID: M6ACROT05722
m6A Regulator RNA binding protein X (RBMX)
m6A Target Circ_TET2
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Drug CP028
Crosstalk ID: M6ACROT05723
m6A Regulator RNA binding protein X (RBMX)
m6A Target Circ_TET2
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Drug dactolisib
Crosstalk ID: M6ACROT05724
m6A Regulator RNA binding protein X (RBMX)
m6A Target Circ_TET2
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Drug perhexiline
References
Ref 1 Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32. doi: 10.1016/j.tox.2006.04.024. Epub 2006 Apr 26.
Ref 2 Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3Beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol Immunother. 2012 Mar;61(3):313-22. doi: 10.1007/s00262-011-1099-y. Epub 2011 Sep 7.
Ref 3 In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16. doi: 10.1124/dmd.109.029835. Epub 2010 Mar 10.
Ref 4 Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494. doi: 10.1371/journal.pone.0075494. eCollection 2013.